Drugs / FURESTEM-CD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02918123 | Jan 2018 → Dec 2021 | psoriasis | Kang Stem Biotech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FURESTEM-CD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02918123 ↗ |
| Modality | Cell therapy | “FURSTEM-CD Inj. has huge possibility as cell therapy products for plaque-type Psoriasis patients.” NCT02918123 ↗ |
| Route | Subcutaneous | “Patients will be treated FURESTEM-CD Inj. Subcutaneous injection” NCT02918123 ↗ |